| [1] |
Bahl S, Roses RE, Sharma A, et al. Asymptomatic changes in cardiac function can occur in ductal carcinoma-in-situ patients following treatment with HER-2/neu-pulsed dendritic cell vaccines [J]. Am J Surg,2009,198(4):488-494.
|
| [2] |
张欢,吴斌. 乳腺癌免疫治疗的研究进展[J/CD]. 中华乳腺病杂志(电子版),2015,9(4):264-269.
|
| [3] |
Wiedermann U,Wiltschke C,Jasinska J,et al. A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study[J]. Breast Cancer Res Treat,2010,119(3):673-683.
|
| [4] |
Pichinuk E, Benhar I, Jacobi O, et al. Antibody targeting of cellbound MUC1 SEA domain kills tumor cells[J]. Cancer Res,2012,72(13):3324-3336.
|
| [5] |
Shumway NM, Ibrahim N, Ponniah S, et al. Therapeutic breast cancer vaccines: a new strategy for early-stage disease [J]. Bio Drugs,2009,23(5):277-287.
|
| [6] |
Strauss L,Bergmann C,Szczepanski M,et al. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta 1 mediates suppression in the tumor microenvironment[J]. Clin Cancer Res,2007,13(15 Pt 1):4345-4354.
|
| [7] |
Sakaguchi S, Miyara M, Costantino CM, et al. FOXP3+ regulatory T cells in the human immune system[J]. Nat Rev Immunol, 2010,10(7):490-500.
|
| [8] |
Byrne WL, Mills KH, Lederer JA, et al. Targeting regulatory T cells in cancer[J]. Cancer Res,2011,71(22):6915-6920.
|
| [9] |
Cao X, Cai SF, Fehniger TA, et al. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance[J]. Immunity,2007,27(4):635-646.
|
| [10] |
于海明,杨俊兰,焦顺昌.乳腺癌肿瘤免疫微环境研究进展[J]. 解放军医学院学报,2013,34(6):664-666,669.
|
| [11] |
任莉莉,邓春艳,蒋锦杏,等. 细胞免疫治疗对乳腺癌患者Treg 细胞表达的影响[J]. 山西医科大学学报,2015,46(7):672-675.
|
| [12] |
Gobert M, Treilleux I, Bendriss-Vermare N, et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome [J]. Cancer Res,2009,69(5):2000-2009.
|
| [13] |
Liu F,Lang R, Zhao J, et al. CD8+ cytotoxic T cell and FOXP3+regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes[J]. Breast Cancer Res Treat,2011,130 (2):645-655.
|
| [14] |
Aruga T, Suzuki E, Saji S, et al. A low number of tumor-infiltrating FOXP3-positive cells during primary systemic chemotherapy correlates with favorable anti-tumor response in patients with breast cancer[J].Oncol Rep,2009,22(2):273-278.
|
| [15] |
Zou W. Regulatory T cells, tumour immunity and immunotherapy [J].Nat Rev Immunol,2006,6(4):295-307.
|
| [16] |
Beyer M, Schultze JL. Regulatory T cells in cancer [J]. Blood,2006,108(3):804-811.
|
| [17] |
Nakanishi J, Wada Y, Matsumoto K, et al. Overexpression of B7-H1(PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers [J]. Cancer Immunol Immunother,2007,56(8):1173-1182.
|
| [18] |
Curiel TJ,Wei S,Dong H,et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity [J]. Nat Med, 2003,9(5):562-567.
|
| [19] |
Ohaegbulam KC, Assal A, Lazar-Molnar E, et al. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway [J].Trends Mol Med,2015,21(1):24-33.
|
| [20] |
Raedler LA. Opdivo (nivolumab):second PD-1 inhibitor receives FDA approval for unresectable or metastatic melanoma[J]. Am Health Drug Benefits,2015,8(Spec Feature):180-183.
|
| [21] |
Sigal LH. Basic science for the clinician 55: CTLA-4 [J]. J Clin Rheumatol,2012,18(3):155-158.
|
| [22] |
Wang XY,Zuo D,Sarkar D,et al. Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma [J].Expert Opin Pharmacother,2011,12(17):2695-2706.
|
| [23] |
李明月. MMPs 抑制剂通过改善肿瘤微环境提高CTLA-4 抗体治疗乳腺癌的实验研究[D].长春:吉林大学,2015.
|
| [24] |
王建霞. 联合抗CTLA-4 抗体及JAK2 抑制剂治疗小鼠乳腺癌的实验研究[D]. 长春:吉林大学,2014.
|
| [25] |
沈文状,董鸿,张林,等. 抗CTLA-4 抗体联合阿霉素治疗小鼠乳腺癌的疗效及机制分析[J]. 重庆医学,2015,44(23):3172-3175.
|
| [26] |
Lakshmi Narendra B, Eshvendar Reddy K, Shantikumar S, et al.Immune system: a double-edged sword in cancer [J]. Inflamm Res,2013,62(9):823-834.
|
| [27] |
Kim HJ, Barnitz RA, Kreslavsky T, et al. Stable inhibitory activity of regulatory T cells requires the transcription factor Helios[J]. Science,2015,350(6258):334-339.
|